CR6530A - Metodo para inhibir la agregacion de proteinas amiloidesy formacion de imagenes de depositos amiloides utilizando derivados de isoindolina - Google Patents

Metodo para inhibir la agregacion de proteinas amiloidesy formacion de imagenes de depositos amiloides utilizando derivados de isoindolina

Info

Publication number
CR6530A
CR6530A CR6530A CR6530A CR6530A CR 6530 A CR6530 A CR 6530A CR 6530 A CR6530 A CR 6530A CR 6530 A CR6530 A CR 6530A CR 6530 A CR6530 A CR 6530A
Authority
CR
Costa Rica
Prior art keywords
amiloid
aggregation
inhibiting
proteins
deposits
Prior art date
Application number
CR6530A
Other languages
English (en)
Inventor
Elizabeth Augelli-Szafran Corinne
Lai Yingjie
Theresa Sakkab Annette
Craswell Walker Lary
Original Assignee
Warner Lambert Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co filed Critical Warner Lambert Co
Publication of CR6530A publication Critical patent/CR6530A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0446—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0453—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/041—Heterocyclic compounds
    • A61K51/044—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins
    • A61K51/0455—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine, rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Optics & Photonics (AREA)
  • Physics & Mathematics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Radiology & Medical Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Se refiere a un método para inhibir la agregación de proteínas amiloides y la información de imágenes de depósitos amiloides. Más particularmente se refiere a un método para inhibir la agregación de proteínas amiloides a fin de tratar el mal de Alzheimer utilizando derivados de isoindolina.
CR6530A 1999-06-10 2001-12-07 Metodo para inhibir la agregacion de proteinas amiloidesy formacion de imagenes de depositos amiloides utilizando derivados de isoindolina CR6530A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US13854399P 1999-06-10 1999-06-10

Publications (1)

Publication Number Publication Date
CR6530A true CR6530A (es) 2004-03-24

Family

ID=22482508

Family Applications (1)

Application Number Title Priority Date Filing Date
CR6530A CR6530A (es) 1999-06-10 2001-12-07 Metodo para inhibir la agregacion de proteinas amiloidesy formacion de imagenes de depositos amiloides utilizando derivados de isoindolina

Country Status (38)

Country Link
EP (1) EP1192131B1 (es)
JP (1) JP2003502313A (es)
KR (1) KR20020012266A (es)
CN (1) CN1156445C (es)
AP (1) AP1398A (es)
AT (1) ATE272623T1 (es)
AU (1) AU777747B2 (es)
BG (1) BG106291A (es)
BR (1) BR0011446A (es)
CA (1) CA2373394A1 (es)
CR (1) CR6530A (es)
CZ (1) CZ20014366A3 (es)
DE (1) DE60012742T2 (es)
DK (1) DK1192131T3 (es)
DZ (1) DZ3262A1 (es)
EA (1) EA004405B1 (es)
EE (1) EE200100666A (es)
ES (1) ES2223531T3 (es)
GE (1) GEP20043407B (es)
HK (1) HK1046283B (es)
HR (1) HRP20020027A2 (es)
HU (1) HUP0201586A2 (es)
IL (1) IL146455A0 (es)
IS (1) IS6162A (es)
MA (1) MA26807A1 (es)
MX (1) MXPA01011112A (es)
NO (1) NO20015992L (es)
NZ (1) NZ515619A (es)
OA (1) OA11958A (es)
PL (1) PL352294A1 (es)
PT (1) PT1192131E (es)
SI (1) SI1192131T1 (es)
SK (1) SK17622001A3 (es)
TR (1) TR200200257T2 (es)
UA (1) UA64842C2 (es)
WO (1) WO2000076969A1 (es)
YU (1) YU86801A (es)
ZA (1) ZA200109164B (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000076489A2 (en) * 1999-06-10 2000-12-21 Warner-Lambert Company Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
US6972287B1 (en) 1999-06-10 2005-12-06 Pfizer Inc. Method of inhibiting amyloid protein aggregation and imaging amyloid deposits
PE20020394A1 (es) 2000-08-18 2002-06-21 Agouron Pharma Compuestos de pirazol y composiciones farmaceuticas que los contienen, que modulan y/o inhiben la actividad de erab/hadh2
CA2357450A1 (en) * 2000-09-29 2002-03-29 Warner-Lambert Company Phenoxazine analogs useful as amyloid aggregation inhibitors and treatment of alzheimer's disease and disorders related to amyloidosis
GB0031302D0 (en) 2000-12-21 2001-01-31 Glaxo Group Ltd Napthalene derivatives
AR042206A1 (es) * 2002-11-26 2005-06-15 Novartis Ag Acidos fenilaceticos y derivados
GB2404855A (en) * 2003-07-07 2005-02-16 Pantherix Ltd Arylcarboxylic acid derivatives and their therapeutic use
AR061623A1 (es) 2006-06-26 2008-09-10 Novartis Ag Derivados de acido fenilacetico
EP2102165A2 (en) * 2006-11-24 2009-09-23 AC Immune S.A. N-(methyl)-1h-pyrazol-3-amine, n-(methyl)-pyridin-2-amine and n-(methyl)-thiazol-2-amine derivatives for the treatment of diseases associated with amyloid or amyloid-like proteins, like e.g. alzheimer's
AU2008215948A1 (en) 2007-02-12 2008-08-21 Merck & Co., Inc. Piperazine derivatives for treatment of AD and related conditions
HUE043090T2 (hu) * 2008-06-09 2019-08-28 Univ Muenchen Ludwig Maximilians Gyógyszerek fehérjék aggregálódásának gátlására olyan betegségeknél, amelyek fehérje-aggregálódással és/vagy neurodegeneratív megbetegedésekkel függnek össze
WO2010089292A1 (en) 2009-02-06 2010-08-12 Ortho-Mcneil-Janssen Pharmaceuticals, Inc Novel substituted bicyclic heterocyclic compounds as gamma secretase modulators
TWI461425B (zh) 2009-02-19 2014-11-21 Janssen Pharmaceuticals Inc 作為伽瑪分泌酶調節劑之新穎經取代的苯并唑、苯并咪唑、唑并吡啶及咪唑并吡啶衍生物類
EP2427453B1 (en) * 2009-05-07 2013-07-17 Janssen Pharmaceuticals, Inc. Substituted indazole and aza-indazole derivatives as gamma secretase modulators
EA021047B1 (ru) 2009-07-15 2015-03-31 Янссен Фармасьютикалз, Инк. Замещенные производные триазола и имидазола в качестве модуляторов гамма-секретазы
PE20121511A1 (es) 2010-01-15 2012-12-06 Janssen Pharmaceuticals Inc Novedosos derivados biciclicos de triazol sustituidos como moduladores de gamma secretasa
CA2827969A1 (en) 2011-03-24 2012-09-27 Janssen Pharmaceuticals, Inc. Novel substituted triazolyl piperazine and triazolyl piperidine derivatives as gamma secretase modulators
EA023045B1 (ru) 2011-07-15 2016-04-29 Янссен Фармасьютикалз, Инк. Новые замещенные производные индола в качестве модуляторов гамма-секретазы
JP6106745B2 (ja) 2012-05-16 2017-04-05 ヤンセン ファーマシューティカルズ，インコーポレーテッド （特に）アルツハイマー病の治療に有用な置換３，４−ジヒドロ−２Ｈ−ピリド［１，２−ａ］ピラジン−１，６−ジオン誘導体
US10112943B2 (en) 2012-12-20 2018-10-30 Janssen Pharmaceutica Nv Substituted imidazoles as gamma secretase modulators
WO2014111457A1 (en) 2013-01-17 2014-07-24 Janssen Pharmaceutica Nv Novel substituted pyrido-piperazinone derivatives as gamma secretase modulators
US10562897B2 (en) 2014-01-16 2020-02-18 Janssen Pharmaceutica Nv Substituted 3,4-dihydro-2H-pyrido[1,2-a]pyrazine-1,6-diones as gamma secretase modulators
CN105636951B (zh) * 2014-04-14 2018-05-15 上海恒瑞医药有限公司 酰胺类衍生物及其可药用盐、其制备方法及其在医药上的应用
JP2017527559A (ja) * 2014-08-29 2017-09-21 シーエイチディーアイ ファウンデーション，インコーポレーテッド ハンチントンタンパク質のイメージング用プローブ
EP3798214B1 (en) 2014-10-06 2022-09-14 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
EP3436446B1 (en) 2016-03-31 2023-06-07 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator
SG10201913595YA (en) 2016-09-30 2020-02-27 Vertex Pharma Modulator of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
MA49235B1 (fr) 2016-12-09 2021-02-26 Vertex Pharma Modulateur de régulateur de conductance transmembranaire de fibrose kystique, compositions pharmaceutiques, procédés de traitement et procédé de fabrication du modulateur
WO2018140186A1 (en) * 2017-01-28 2018-08-02 Kingchem Life Science Llc A process for preparing 5-phenoxy-1(3h)isobenzofuranone
EP3634402B1 (en) 2017-06-08 2026-01-21 Vertex Pharmaceuticals Incorporated Methods of treatment for cystic fibrosis
BR112020000941A2 (pt) 2017-07-17 2020-07-21 Vertex Pharmaceuticals Incorporated métodos de tratamento para fibrose cística
TWI799435B (zh) 2017-08-02 2023-04-21 美商維泰克斯製藥公司 製備化合物之製程
CN109232533A (zh) * 2017-09-28 2019-01-18 北京越之康泰生物医药科技有限公司 氮杂环类衍生物、其制备方法及其医药用途
IL273831B2 (en) 2017-10-19 2024-10-01 Vertex Pharma Crystalline forms and compositions of cftr modulators
CN111757874B (zh) 2017-12-08 2024-03-08 弗特克斯药品有限公司 用于制备囊性纤维化跨膜传导调节因子的调节剂的方法
TWI810243B (zh) 2018-02-05 2023-08-01 美商維泰克斯製藥公司 用於治療囊腫纖化症之醫藥組合物
US11414439B2 (en) 2018-04-13 2022-08-16 Vertex Pharmaceuticals Incorporated Modulators of cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
AU2022306297A1 (en) 2021-07-09 2024-02-08 Plexium, Inc. Aryl compounds and pharmaceutical compositions that modulate ikzf2

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5552426A (en) * 1994-04-29 1996-09-03 Eli Lilly And Company Methods for treating a physiological disorder associated with β-amyloid peptide

Also Published As

Publication number Publication date
IS6162A (is) 2001-11-15
EA200101133A1 (ru) 2002-06-27
DK1192131T3 (da) 2004-12-13
GEP20043407B (en) 2004-05-10
JP2003502313A (ja) 2003-01-21
CZ20014366A3 (cs) 2002-11-13
UA64842C2 (uk) 2004-03-15
MA26807A1 (fr) 2004-12-20
EP1192131A1 (en) 2002-04-03
MXPA01011112A (es) 2002-06-04
TR200200257T2 (tr) 2002-06-21
DE60012742D1 (de) 2004-09-09
AP2002002389A0 (en) 2002-03-31
EE200100666A (et) 2003-02-17
DZ3262A1 (fr) 2000-12-12
ZA200109164B (en) 2003-02-06
SI1192131T1 (en) 2004-12-31
SK17622001A3 (sk) 2003-06-03
DE60012742T2 (de) 2005-01-13
HRP20020027A2 (en) 2005-02-28
HK1046283B (zh) 2005-01-07
AP1398A (en) 2005-04-21
OA11958A (en) 2006-04-13
EP1192131B1 (en) 2004-08-04
HK1046283A1 (en) 2003-01-03
CA2373394A1 (en) 2000-12-21
AU777747B2 (en) 2004-10-28
PT1192131E (pt) 2004-11-30
AU5312000A (en) 2001-01-02
NZ515619A (en) 2003-05-30
CN1156445C (zh) 2004-07-07
YU86801A (sh) 2004-07-15
HUP0201586A2 (en) 2002-08-28
NO20015992D0 (no) 2001-12-07
BR0011446A (pt) 2002-03-19
IL146455A0 (en) 2002-07-25
NO20015992L (no) 2002-02-06
CN1355790A (zh) 2002-06-26
KR20020012266A (ko) 2002-02-15
WO2000076969A1 (en) 2000-12-21
PL352294A1 (en) 2003-08-11
BG106291A (bg) 2002-05-31
ES2223531T3 (es) 2005-03-01
EA004405B1 (ru) 2004-04-29
ATE272623T1 (de) 2004-08-15

Similar Documents

Publication Publication Date Title
CR6530A (es) Metodo para inhibir la agregacion de proteinas amiloidesy formacion de imagenes de depositos amiloides utilizando derivados de isoindolina
CR6528A (es) Metodo para inhibir la agregcion de proteinas amiloidesy formacion de imagenes de depositos amiloides
ES2116600T3 (es) Metodos y composiciones para mejorar el contraste de imagenes.
FR2852700B1 (fr) Procede et installation d'imagerie acousto-optique.
SI1553985T1 (sl) Bifenili kot sredstva za slikanje pri Alzheimerjevi bolezni
EP1299777A4 (en) METHOD AND DEVICE FOR MINIMIZING VISUAL ARTEFACT PRODUCED BY ILLUMINATED PHOTOGRAPHIC MACHINES ON IMAGING
BR0011440A (pt) Derivados de rodanina e seu uso na inibição e formação de imagens de amilóides
IT1317576B1 (it) Metodo e sistema per l'assicurazione di un investimento in titoliazionari e similari.
TH28330S1 (th) ท่อ
TH99401S (th) ท่อ
TH100905S (th) ท่อร้อยสายไฟ
TH29222S1 (th) ท่อร้อยสายไฟ
TH59736S (th) กล่อง
TH13651S1 (th) "ตู้เย็น"
TH13652S1 (th) "ตู้เย็น"
TH44134S (th) "ตู้เย็น"
TH27355S1 (th) จาน
TH62634S (th) จาน
TH13634S1 (th) "กล่อง"
TH48555S (th) "กล่อง"
TH52031S (th) ลวดลายสันแฟ้ม
TH15074S1 (th) ลวดลายสันแฟ้ม
TH60434S (th) "ชุดชั้นใน"
TH9936S1 (th) กล่อง
TH29400S1 (th) เก้าอี้

Legal Events

Date Code Title Description
FA Abandonment or withdrawal (granting procedure)